CytomX Therapeutics CTMX
NASDAQ CTMX
$2.75 +0.06 (+2.23%)
At close: Sep 29, 2026 · 4:00 PM EDT

CytomX Therapeutics (CTMX) Non-Current Debt (2014)

Updated

CytomX Therapeutics' Non-Current Debt came in at $1.57 million for Q4 2014.

Analysis

CytomX Therapeutics (CTMX) Non-Current Debt (2014) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 37.34 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 62.48 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 51.08 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -108.00 Mn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 51.86 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 23.83 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 60.50 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 CytomX Therapeutics 586.15 Mn -371.52 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2014 1.57 Mn
API Access

CytomX Therapeutics Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=CTMX&period=max&api_key=YOUR_API_KEY